ACTRN12608000592347招募中未知
A Randomised, Double-Blind, Cross-Over Study to Investigate the Effects of Hyperoxia on Carbon Dioxide Levels and Ventilation In Patients with Obesity Hypoventilation Syndrome
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Educational / counselling / training
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- o limit 至 o limit（—）
- 性别
- All
入选标准
- •Patients with a new diagnosis of Obesity Hypoventilation Syndrome:
- •1. Body mass index (BMI) >30kg/m2,
- •2. Daytime hypercapnia (pCO2 >45mmHg)
排除标准
- •1. Diagnosis of chronic airflow obstruction: post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) to Forced Vital Capacity (FVC) ratio <0.7 and Forced Expiratory Volume in 1 second (FEV1) <80% predicted and > 10 pack year smoking history
- •2. Patients already receiving treatment with Continuous Positive Airway Pressure (CPAP) or non-invasive positive pressure ventilation
研究者
相似试验
进行中（未招募）
1 期
Functional MRI study of the central effects of erenumab in patients with episodic migraine.Episodic migraineMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-004875-11-ITOVARTIS FARMA S.P.A.140
进行中（未招募）
1 期
A Randomized, Double-Blind, Cross-Over Study Comparing the Pharmacodynamic Response in Subjects with Acute Coronary Syndrome Receiving 14 Days 10-mg Maintenance Dose Prasugrel (LY640315) versus 14 Days 150-mg Maintenance Dose Clopidogrel After Using a 900-mg Loading Dose of Clopidogrel to Reduce Ongoing Platelet Activation – The ACAPULCO Study - ACAPULCO StudyEUCTR2006-002618-37-FREli Lilly and Company70
进行中（未招募）
1 期
Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, delivered with the Respimat® Inhaler, after 3 Weeks of Once Daily (5 µg [2 actuations of 2.5 mg], 10 mg [2 actuations of 5 mg]) or Twice Daily (2 µg [2 actuations of 1 mg], 5 mg [2 actuations of 2.5 mg]) Administration in Patients with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2008-006334-10-BESCS Boehringer Ingelheim Comm.V48
进行中（未招募）
1 期
A Double-Blind, Randomized, Crossover Study of the Recovery of FACTANE 100 versus 200 IU/ml followed by an Open-Label Safety Study of FACTANE 200 IU/ml in Previously Treated Patients With Severe (FVIII:C<1%) Haemophilia AEUCTR2009-013227-28-FRFB BIOTECHNOLOGIES13
进行中（未招募）
1 期
Randomised, Double-Blind, Cross-over Study to Determine the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, delivered with the Respimat® Inhaler, after 3 Weeks of Once Daily (5 mcg [2 actuations of 2,5 mg], 10 mcg [2 actuations of 5 mcg]) or Twice Daily (2 mcg [2 actuations of 1 mcg], 5 mg [2 actuations of 2,5 mcg]) Administration in Patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-006334-10-NLBoehringer Ingelheim BV48